GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » EPS (Diluted)

Calithera Biosciences (Calithera Biosciences) EPS (Diluted) : $-8.65 (TTM As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences EPS (Diluted)?

Calithera Biosciences's Earnings per Share (Diluted) for the three months ended in Dec. 2022 was $-1.45. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-8.65.

Calithera Biosciences's EPS (Basic) for the three months ended in Dec. 2022 was $-1.45. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was $-5.43.

Calithera Biosciences's EPS without NRI for the three months ended in Dec. 2022 was $-1.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $-8.98.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Calithera Biosciences EPS (Diluted) Historical Data

The historical data trend for Calithera Biosciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences EPS (Diluted) Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.80 -38.00 -26.20 -31.16 -7.94

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.40 -3.60 -1.59 -2.01 -1.45

Competitive Comparison of Calithera Biosciences's EPS (Diluted)

For the Biotechnology subindustry, Calithera Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's PE Ratio falls into.



Calithera Biosciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Calithera Biosciences's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-39.65-0)/4.992
=-7.94

Calithera Biosciences's Diluted EPS for the quarter that ended in Dec. 2022 is calculated as

Diluted EPS (Q: Dec. 2022 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.936-0)/4.870
=-1.42

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calithera Biosciences  (OTCPK:CALA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Calithera Biosciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (Calithera Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Executives
Deepika Pakianathan director, 10 percent owner 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford officer: SR. VP, CLINICAL DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman director 21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux director, officer: PRESIDENT AND CEO C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux officer: SR. VP, DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose officer: CHIEF MEDICAL OFFICER 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong officer: VP, FINANCE 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Calithera Biosciences (Calithera Biosciences) Headlines